Ligand ID: RXT


Drugbank ID:
DB08877
(Ruxolitinib)


Indication:
Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).

Get human targets for RXT in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'RXT' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A 250
VAL A 202
ALA A 206
TYR A 209
LEU A 268
1.70A21.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A 115
GLY A  29
VAL A 148
GLY A  11
ASN A  95
1.66A21.18
None
None
None
None
DMS  A 403 ( 4.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 9
LEU A 250
VAL A 202
ALA A 206
TYR A 209
LEU A 268
1.80A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
LEU C 115
GLY C  29
VAL C 148
GLY C  11
ASN C  95
1.62A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 9
LEU C 250
VAL C 202
ALA C 206
TYR C 209
LEU C 268
1.77A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 9
LEU D 250
VAL D 202
ALA D 206
TYR D 209
LEU D 268
1.75A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
LEU D 115
GLY D  29
VAL D 148
GLY D  11
ASN D  95
1.61A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6vxs NSP3
(SARS-CoV-2)		5 / 11
LEU A 109
ALA A 112
TYR A 113
ASN A  40
ALA A  39
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6vxs NSP3
(SARS-CoV-2)		5 / 11
LEU B 109
ALA B 112
TYR B 113
ASN B  40
ALA B  39
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6vxs NSP3
(SARS-CoV-2)		5 / 11
LEU A 126
GLY A  48
ALA A 124
ALA A  21
ASP A  22
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU B 981
ALA B 989
ASN B 969
LEU B 996
ALA B 972
1.21A11.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU C 981
ALA C 989
ASN C 969
LEU C 996
ALA C 972
1.22A11.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w4b NSP9
(SARS-CoV-2)		5 / 9
LEU B  10
ALA B  44
TYR B  32
GLY B 105
LEU B 104
1.76A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w4h NSP10
(SARS-CoV-2)		5 / 11
LEU B4284
GLY B4362
LEU B4328
ALA B4276
ASP B4275
1.48A16.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w61 NSP10
(SARS-CoV-2)		5 / 11
LEU B4284
GLY B4362
LEU B4328
ALA B4276
ASP B4275
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 9
LEU A 250
VAL A 202
ALA A 206
TYR A 209
LEU A 268
1.80A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
LEU B  93
VAL B  82
GLY B  79
ASN B  72
LEU B  75
1.70A20.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
LEU B 109
ALA B 112
TYR B 113
ASN B  40
ALA B  39
1.57A
None
None
None
MES  B 201 ( 3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
LEU A 126
GLY A  48
ALA A 124
ALA A  21
ASP A  22
1.51A
AMP  A 201 ( 4.4A)
AMP  A 201 ( 3.6A)
None
None
AMP  A 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
GLY B  47
VAL B  49
ALA B 124
GLY B  97
ALA B 129
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
LEU B 123
VAL B  35
ALA B  27
ASN B  54
ALA B  56
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
LEU B 108
VAL B  77
ALA B 112
ASN B 101
ALA B 134
1.78A20.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
LEU A 123
VAL A  35
ALA A  27
ASN A  54
ALA A  56
1.68A20.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
LEU A  93
VAL A  82
GLY A  79
ASN A  72
LEU A  75
1.77A20.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
LEU A 109
ALA A 112
TYR A 113
ASN A  40
ALA A  39
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
LEU B 126
GLY B  48
ALA B 124
ALA B  21
ASP B  22
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w6y NSP3
(SARS-CoV-2)		5 / 11
GLY A  47
VAL A  49
ALA A 124
GLY A  97
ALA A 129
1.58A
None
AMP  A 201 ( 3.7A)
None
None
AMP  A 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w75 NSP10
(SARS-CoV-2)		5 / 11
LEU B4284
GLY B4362
LEU B4328
ALA B4276
ASP B4275
1.49A16.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6w75 NSP10
(SARS-CoV-2)		5 / 11
LEU D4284
GLY D4362
LEU D4328
ALA D4276
ASP D4275
1.47A16.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wcf NSP3
(SARS-CoV-2)		5 / 11
LEU A 126
GLY A  48
ALA A 124
ALA A  21
ASP A  22
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wen NSP3
(SARS-CoV-2)		5 / 11
LEU A 109
ALA A 112
TYR A 113
ASN A  40
ALA A  39
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wen NSP3
(SARS-CoV-2)		5 / 11
LEU A 153
VAL A 151
ALA A 124
LEU A 127
ALA A 112
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wey NSP3
(SARS-CoV-2)		5 / 11
LEU A 330
GLY A 252
ALA A 328
ALA A 225
ASP A 226
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wey NSP3
(SARS-CoV-2)		5 / 11
LEU A 313
ALA A 316
TYR A 317
ASN A 244
ALA A 243
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wjt NSP10
(SARS-CoV-2)		5 / 11
LEU B4284
GLY B4362
LEU B4328
ALA B4276
ASP B4275
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wjt NSP10
(SARS-CoV-2)		5 / 11
LEU D4284
GLY D4362
LEU D4328
ALA D4276
ASP D4275
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wkq NSP10
(SARS-CoV-2)		5 / 11
LEU D4284
GLY D4362
LEU D4328
ALA D4276
ASP D4275
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wkq NSP10
(SARS-CoV-2)		5 / 11
LEU B4284
GLY B4362
LEU B4328
ALA B4276
ASP B4275
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 9
LEU A 250
VAL A 202
ALA A 206
TYR A 209
LEU A 268
1.79A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU D 123
GLY D  85
VAL D  35
ALA D 124
ASN A 159
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
GLY A  47
VAL A  49
ALA A 124
GLY A  97
ALA A 129
1.53A
APR  A 201 (-4.1A)
APR  A 201 (-3.8A)
None
None
APR  A 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU B 109
ALA B 112
TYR B 113
ASN B  40
ALA B  39
1.59A
None
None
None
APR  B 201 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A 123
VAL A  35
ALA A  27
ASN A  54
ALA A  56
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU C 109
GLY C 103
ALA C 112
TYR C 113
ALA C  39
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU D 123
VAL D  35
ALA D  27
ASN D  54
ALA D  56
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A 109
ALA A 112
TYR A 113
ASN A  40
ALA A  39
1.60A
None
None
None
APR  A 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A 126
GLY A  48
ALA A 124
ALA A  21
ASP A  22
1.55A
None
APR  A 201 (-3.5A)
None
None
APR  A 201 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU B 126
GLY B  48
ALA B 124
ALA B  21
ASP B  22
1.59A
None
APR  B 201 (-3.4A)
None
None
APR  B 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU B 123
GLY B  85
VAL B  35
ALA B 124
ASN C 159
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU C 109
ALA C 112
TYR C 113
ASN C  40
ALA C  39
1.61A
None
None
None
APR  C 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
GLY C  47
VAL C  49
ALA C 124
GLY C  97
ALA C 129
1.52A
APR  C 201 (-4.1A)
APR  C 201 (-3.8A)
None
None
APR  C 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU D 126
GLY D  48
ALA D 124
ALA D  21
ASP D  22
1.59A
None
APR  D 201 (-3.5A)
None
None
APR  D 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU B 123
VAL B  35
ALA B  27
ASN B  54
ALA B  56
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU D 109
ALA D 112
TYR D 113
ASN D  40
ALA D  39
1.59A
None
None
None
APR  D 201 (-3.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
GLY B  47
VAL B  49
ALA B 124
GLY B  97
ALA B 129
1.52A
APR  B 201 (-4.0A)
APR  B 201 (-3.7A)
None
None
APR  B 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU C 126
GLY C  48
ALA C 124
ALA C  21
ASP C  22
1.59A
APR  C 201 (-4.9A)
APR  C 201 (-3.5A)
None
None
APR  C 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU B  93
GLY B  85
VAL B  35
ASN B  54
ALA B  50
1.54A
None
None
None
None
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
GLY D  47
VAL D  49
ALA D 124
GLY D  97
ALA D 129
1.51A
APR  D 201 (-4.2A)
APR  D 201 (-3.6A)
None
None
APR  D 201 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6wq3 NSP10
(SARS-CoV-2)		5 / 11
LEU B4284
GLY B4362
LEU B4328
ALA B4276
ASP B4275
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_B_RXTB601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6y2e REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 9
LEU A 250
VAL A 202
ALA A 206
TYR A 209
LEU A 268
1.78A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A 250
VAL A 202
ALA A 206
TYR A 209
LEU A 268
1.71A21.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A 115
GLY A  29
VAL A 148
GLY A  11
ASN A  95
1.66A21.53
None
None
None
None
DMS  A 406 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ym0 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
VAL E 524
ALA E 363
GLY E 431
LEU E 513
ALA E 397
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
GLY B  47
VAL B  49
ALA B 124
GLY B  97
ALA B 129
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU E 153
VAL E 151
ALA E 124
LEU E 127
ALA E 112
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU D 126
GLY D  48
ASN C  87
ALA D  21
ASP D  22
1.28A
None
EDO  D 209 ( 4.7A)
None
None
EDO  D 209 ( 3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU B 109
GLY B 103
ALA B 112
TYR B 113
ALA B  39
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU B 126
GLY B  48
ALA B 124
ALA B  21
ASP B  22
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU D 109
ALA D 112
TYR D 113
ASN D  40
ALA D  39
1.55A
EDO  D 204 ( 4.5A)
None
None
EDO  D 206 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU C 153
VAL C 151
ALA C 124
LEU C 127
ALA C 112
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU C 109
ALA C 112
TYR C 113
ASN C  40
ALA C  39
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU C 126
GLY C  48
ALA C 124
ALA C  21
ASP C  22
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU A 126
GLY A  48
ALA A 124
ALA A  21
ASP A  22
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU D 126
GLY D  48
ALA D 124
ALA D  21
ASP D  22
1.53A
None
EDO  D 209 ( 4.7A)
None
None
EDO  D 209 ( 3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU E 109
ALA E 112
TYR E 113
ASN E  40
ALA E  39
1.57A
None
None
None
EPE  E 202 (-4.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU A 109
ALA A 112
TYR A 113
ASN A  40
ALA A  39
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU B 109
ALA B 112
TYR B 113
ASN B  40
ALA B  39
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU E 126
GLY E  48
ALA E 124
ALA E  21
ASP E  22
1.54A
None
EPE  E 202 ( 4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU A 109
ALA A 112
TYR A 113
ASN A  40
ALA A  39
1.55A
None
None
None
APR  A 201 (-3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU E 126
GLY E  48
ALA E 124
ALA E  21
ASP E  22
1.47A
APR  E 201 (-4.7A)
APR  E 201 (-3.4A)
None
None
APR  E 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU C 126
GLY C  48
ALA C 124
ALA C  21
ASP C  22
1.47A
APR  C 201 (-4.8A)
APR  C 201 (-3.5A)
None
None
APR  C 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU B 122
GLY B  85
VAL B  35
ALA B 124
ALA B  39
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU D 109
ALA D 112
TYR D 113
ASN D  40
ALA D  39
1.55A
None
None
None
APR  D 201 (-3.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
GLY C  47
VAL C  49
ALA C 124
GLY C  97
ALA C 129
1.52A
APR  C 201 (-4.3A)
APR  C 201 (-3.6A)
None
None
APR  C 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU B 109
ALA B 112
TYR B 113
ASN B  40
ALA B  39
1.58A
None
None
None
APR  B 201 (-3.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU A 153
VAL A 151
ALA A 124
LEU A 127
ALA A 112
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU C 109
ALA C 112
TYR C 113
ASN C  40
ALA C  39
1.55A
None
None
None
APR  C 201 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU D 126
GLY D  48
ALA D 124
ALA D  21
ASP D  22
1.48A
APR  D 201 (-4.5A)
EDO  D 204 ( 3.4A)
None
None
APR  D 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
GLY D  47
VAL D  49
ALA D 124
GLY D  97
ALA D 129
1.54A
APR  D 201 ( 4.3A)
APR  D 201 (-3.7A)
None
None
APR  D 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU C 153
VAL C 151
ALA C 124
LEU C 127
ALA C 112
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU B 126
GLY B  48
ALA B 124
ALA B  21
ASP B  22
1.44A
APR  B 201 (-4.7A)
APR  B 201 (-3.5A)
None
None
APR  B 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
GLY B  47
VAL B  49
ALA B 124
GLY B  97
ALA B 129
1.53A
APR  B 201 (-3.6A)
APR  B 201 (-3.7A)
None
None
APR  B 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU E 153
VAL E 151
ALA E 124
LEU E 127
ALA E 112
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU A 126
GLY A  48
ALA A 124
ALA A  21
ASP A  22
1.44A
APR  A 201 (-4.8A)
APR  A 201 (-3.4A)
None
None
APR  A 201 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
GLY A  47
VAL A  49
ALA A 124
GLY A  97
ALA A 129
1.53A
APR  A 201 (-4.1A)
APR  A 201 (-3.7A)
None
None
APR  A 201 ( 3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU D 126
GLY D  48
ASN C  87
ALA D  21
ASP D  22
1.13A
APR  D 201 (-4.5A)
EDO  D 204 ( 3.4A)
None
None
APR  D 201 (-3.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU E 109
ALA E 112
TYR E 113
ASN E  40
ALA E  39
1.58A
None
None
None
APR  E 201 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
GLY E  47
VAL E  49
ALA E 124
GLY E  97
ALA E 129
1.55A
APR  E 201 (-4.4A)
APR  E 201 (-3.7A)
None
None
APR  E 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU C 109
ALA C 112
TYR C 113
ASN C  40
ALA C  39
1.55A
None
None
None
MES  C 201 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU A 126
GLY A  48
ALA A 124
ALA A  21
ASP A  22
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU A 109
ALA A 112
TYR A 113
ASN A  40
ALA A  39
1.56A
None
None
None
MES  A 201 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
GLY C  47
VAL C  49
ALA C 124
GLY C  97
ALA C 129
1.60A
MES  C 201 ( 4.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
GLY A  47
VAL A  49
ALA A 124
GLY A  97
ALA A 129
1.62A
MES  A 201 ( 4.8A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU B 109
ALA B 112
TYR B 113
ASN B  40
ALA B  39
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU C 126
GLY C  48
ALA C 124
ALA C  21
ASP C  22
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 11
LEU B 126
GLY B  48
ALA B 124
ALA B  21
ASP B  22
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 11
LEU A 115
GLY A  29
VAL A 148
GLY A  11
ASN A  95
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		7bqy MAIN PROTEASE

(SARS-CoV-2;
synthetic
construct)		5 / 11
GLY A 174
ALA C   2
GLY A 170
ASN A 133
ALA A 194
1.55A
None
02J  C   1 ( 3.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		7btf NSP8
(SARS-CoV-2)		5 / 11
LEU B 117
GLY B 113
VAL B 115
ASN B 104
ALA B 102
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		7btf NSP12
(SARS-CoV-2)		5 / 11
LEU A 186
GLY A 179
VAL A 182
TYR A 238
LEU A 316
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		7bv1 NSP12
(SARS-CoV-2)		5 / 11
VAL A 860
TYR A 887
GLY A 841
ALA A 866
ASP A 865
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		7bv1 NSP8
(SARS-CoV-2)		5 / 11
LEU B 117
GLY B 113
VAL B 115
ASN B 104
ALA B 102
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		7bv2 NSP12
(SARS-CoV-2)		5 / 11
VAL A 860
TYR A 887
GLY A 841
ALA A 866
ASP A 865
1.62A
None
None
None
None
U  P  18 ( 3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		7bv2 NSP12
(SARS-CoV-2)		5 / 11
LEU A 186
VAL A 182
ALA A 185
LEU A 207
ALA A 125
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4U5J_A_RXTA601_1
(PROTO-ONCOGENE
TYROSINE-PROTEIN
KINASE SRC)		7bv2 NSP12
(SARS-CoV-2)		5 / 11
LEU A 186
GLY A 179
VAL A 182
TYR A 238
LEU A 316
1.57A
None